NIH Is Collapsing 14 K Awards Into Four — and Quietly Ending the Independent Clinical Trial K

On August 12, 2026, the NIH Office of the Director issued NOT-OD-26-098, "Notice of NIH Updates to Career Development (K) Award Programs." It is being presented as a simplification — fewer funding opportunity announcements, less paperwork, clearer eligibility. Most of that framing is accurate.

But buried in the same notice is a policy change that will reshape the early careers of clinician-scientists for a decade: NIH will no longer support K awards under which the awardee leads an independent clinical trial.

There is a virtual open house on September 29, 2026, and a Request for Information on clinical trial research training that closes September 30, 2026. If you are a K applicant, a K awardee, a department chair, or a research administrator, those two dates are the last practical opportunity to shape what replaces the current system.

What is actually consolidating

NIH is folding the individual K notices of funding opportunity into four parent NOFOs, each with a new activity code. The crosswalk:

Four activity codes are unaffected: K00, K12, K43, and K76. Institutional training awards (K12) and the Fogarty and PHS-track mechanisms continue as they are.

The timeline is long enough to plan around and short enough to matter:

• All current K NOFOs — except K00, K12, K43, and K76 — expire by July 13, 2027.
• The new structure applies to applications with due dates on or after October 12, 2027.

That leaves a window between the expiration of the old announcements and the opening of the new ones. Anyone planning a K submission in calendar 2027 needs to confirm, specifically, which announcement they are submitting under and when it closes. "I'll apply for a K08 next year" is no longer a coherent plan — the K08 announcement will not exist in its current form after mid-July 2027.

Note also that the consolidation collapses distinctions that currently carry real meaning. K01 and K25 have served notably different populations — the latter has been the quantitative-scientist-entering-biomedical-research pathway. K08 and K23 have separated laboratory-based from patient-oriented clinician research. Folding them into KR1 and KC1 does not delete those career paths, but it does mean the announcement no longer signals them. The differentiation moves out of the mechanism and into your candidate development plan, where you now have to articulate it yourself.

For readers newer to the alphabet, our primer on decoding NIH R, K, and F series grants covers what each mechanism was designed to do.

The clinical trial change is the one that matters

Here is the language that deserves your attention: K awards will no longer support independent clinical trials. Awardees may not use K funds to conduct or lead a trial. They may gain clinical trial experience through mentor-led activities — participating in a trial their mentor directs. A K awardee who wants to lead their own trial must secure separate funding.

The current system includes K NOFOs explicitly designated "Independent Clinical Trial Required." Those go away.

Consider what that does to a specific, common career path. A junior physician-scientist in, say, cardiology or psychiatry currently competes for a mentored K23 with an independent trial component, runs a small pilot trial under mentorship but as the responsible investigator, generates preliminary data and — critically — a documented record of having led a trial, and uses both to compete for an R01. The trial leadership credential is not incidental to that transition. It is frequently the thing that makes the R01 competitive, because reviewers of a clinical trial R01 want evidence the PI can actually run a trial.

Under the new policy, that credential has to come from somewhere else. The options are all worse:

• Participate in a mentor's trial. Real experience, but the CV line reads as co-investigator, not leader. For an R01 reviewer asking "can this person run a trial," it is weaker evidence.
• Find separate funding for an independent trial while on a K. Possible — foundation awards, institutional pilot funds, an R21 or R34 — but the K effort requirement makes this genuinely hard. K awardees must commit at minimum 9 person-months, equivalent to 75 percent full-time professional effort, to the K project and career development activities. Running a separate trial inside the remaining 25 percent is not realistic for most trials.
• Skip the K entirely and go straight for independent research funding. Viable for a small number of exceptionally well-positioned candidates. For most, it means competing for an R01 against established investigators without the protected time a K provides.

There is a legitimate policy argument behind the change. K awards are career development awards, not research grants; loading an independent trial onto a mentored award arguably distorts both. NIH's reasoning is internally coherent.

But the transition creates a real gap, and NIH knows it — which is precisely why the RFI exists.

The two dates that are actually open right now

Everything above is decided. Two things are not.

The Request for Information on clinical trial research training closes September 30, 2026. NIH is explicitly seeking input on how to strengthen clinical trial research training and career development, including the structure of clinical trial research experiences within mentored K awards. This is the channel through which the replacement pathway gets designed. If your institution trains clinician-scientists, the substantive question to answer is not "please don't do this" — the consolidation is happening — but rather: what mechanism produces a documented trial-leadership credential for a mentored investigator, and what should it look like? Concrete proposals from people who train these investigators are far more useful to NIH at this stage than objections.

The virtual open house is September 29, 2026. One day before the RFI closes. The sequencing is not accidental: attend, learn what NIH is actually planning, then file a comment informed by it. Working backward from a September 30 deadline, that means drafting before the open house and finalizing after.

The paperwork win is real, and smaller than it sounds

Two changes reduce burden on applicants.

Data Management and Sharing Plans are eliminated for K applications. The rationale is sound: K awards develop careers, they do not primarily generate research data, and requiring a full DMS Plan has been a mismatch since the policy took effect. This is a genuine, if modest, reduction in effort.

One caution: the DMS Plan requirement disappearing from the K application does not exempt the underlying research from data sharing obligations attached to other awards. If your K-supported work uses data from an R01 or a repository with its own terms, those terms still apply. The form goes away; the obligations behind it do not.

Review criteria are streamlined to three scored areas: candidate development, research quality, and mentoring environment.

This is a bigger change than it appears. Compressing review into three criteria means each carries proportionally more weight, and mentoring environment is now one-third of a scored review. Institutional commitment letters, mentor track records, and the concrete structure of the mentoring plan are no longer supporting material — they are a third of the score. Candidates at institutions with thin mentoring infrastructure will feel this. Candidates who treat the mentoring section as boilerplate will feel it more.

What each group should do

If you are planning a K application:

Decide whether you are submitting under the current structure or the new one, and commit. Applications due before October 12, 2027 run under existing NOFOs — most of which expire by July 13, 2027. If your science and your mentoring plan are ready, submitting under the current rules is the lower-variance choice: you know the review criteria, you know the format, and if your project includes an independent trial, this is the last window in which a K can support it.

If you are targeting the new structure, build toward three-criterion review now. That means securing a mentoring environment you can describe concretely — named mentors, defined meeting cadence, documented institutional protected time — rather than assembling it in the months before submission.

If you are a current K awardee:

The effort rules are worth re-reading. The 75 percent minimum applies, but during the final two years of a mentored K (of a three-to-five-year award), an awardee who secures a peer-reviewed research grant may reduce K effort from 75 percent to a minimum of 50 percent, provided combined research commitment stays at or above 75 percent. Concurrent compensated work on other projects is permitted within the discretionary 25 percent, as long as those projects' aims are distinct from the K aims. Institutional salary supplementation from non-federal sources is allowed if it relates to the K work and imposes no duties that interfere with it.

If your career plan assumed a trial-leadership credential from your K, start building an alternative route now — a foundation trial award, an R34 planning grant, or a formally documented leadership role within a mentor-led trial that a future reviewer can actually read as leadership.

If you are a chair or research administrator:

Three actions. Inventory which of your faculty are mid-stream on K08, K23, K01, K25, K99, and K24 awards and map each to its successor code, because reporting and internal tracking systems will need the crosswalk before July 2027. Second, audit your mentoring infrastructure against a review in which mentoring environment is one of three scored criteria. Third, decide institutionally how your clinician-scientists will acquire trial leadership experience without a K that funds it — that is a resource question, and departments that answer it with bridge funding or dedicated pilot-trial mechanisms will out-recruit departments that do not.

The wider pattern

The K consolidation is not an isolated action. NIH has been compressing its funding landscape across the board — the same logic drove the restructuring of the Extramural Loan Repayment Programs, which cut six subcategories to three for the FY 2027 cycle (open September 1 through November 19, 2026) and renamed REACH to FOCUS. We covered that change in detail in NIH's Loan Repayment Program Restructuring.

The direction is consistent: fewer doors, broader doors, more of the differentiation pushed from the mechanism into the application itself. For applicants, that is a genuine reduction in navigational overhead and a genuine increase in the burden of self-positioning. When the announcement no longer tells reviewers what kind of scientist you are, your candidate development plan has to.

The open house is September 29. The RFI closes September 30. After that, the clinical trial training pathway gets designed without you.